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Background: Lithium is considered by many as the gold standard medication in the management of bipolar
disorder (BD). However, the clinical response to lithium is heterogeneous, and the molecular basis for this difference
in response is unknown. In the present study, we sought to determine how the peripheral blood gene expression
profiles of patients with bipolar disorder (BD) changed over time following intitiation of treatment with lithium,
and whether differences in those profiles over time were related to the clinical response.
Methods: Illumina Sentrix Beadchip (Human-6v2) microarrays containing > 48,000 transcript probes were used to
measure levels of expression of gene-expression in peripheral blood from 20 depressed subjects with BD prior to
and every two weeks during 8 weeks of open-label treatment with lithium.
Changes in gene-expression were compared between treatment responders (defined as a decrease in the Hamilton
Depression Rating Scale of 50% or more) and non-responders. Pathway analysis was conducted using GeneGO
Metacore software.
Results: 127 genes showed a differential response in responders vs. non-responders. Pathway analysis showed that
regulation of apoptosis was the most significantly affected pathway among these genes. Closer examination of the
time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting
treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were
up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of
cell death (BAD), were down-regulated. In contrast, in lithium non-responders, BCL2 and IRS2 were down-regulated,
while BAK1 and BAD up-regulated at the one-month time-point.
Conclusions: These results suggest that differential changes in the balance of pro- and anti- apoptotic gene-
expression following treatment with lithium may explain some of the heterogeneity in clinical response in BD
patients.
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Bipolar disorder (BD) is a devastating neurobiological
illness, affecting from 0.8% to 1.2% of the population [1-3].
Clinically, the disorder is characterized by episodes of
mania and major depression. However, as with the vast
majority of psychiatric illnesses, the nature of the under-
lying pathophysiology remains poorly understood [4].
Lithium is considered by many as the gold standard medi-
cation in the management of bipolar disorder (BD). It was
the first treatment with demonstrated efficacy in BD [5]
and it is still considered first line treatment for acute
mania, acute bipolar depression, and maintenance treat-
ment [6-8]. It is also the only medication to be consist-
ently associated with a reduction in suicidal ideation or
attempts in patients with BD [9-11].
Previous studies have investigated polymorphisms
in a variety of genes including serotonin transporter,
glycogen synthase kinase-3beta, inositol polyphosphatase
1-phosphate, brain-derived neurotrophic factor and acti-
vator protein 2beta, and found that these variants are
not predictive factors for response to lithium [12,13].
Genome-wide association studies have also been con-
ducted to identify common gene variants that may be
associated with lithium response [14,15]. While some
loci with suggestive evidence for linkage have been
found [14], to date no SNPs have met the threshold for
genome-wide significance. Thus, despite decades of work
related to this topic, the molecular basis for the hetero-
geneity in response to treatment with lithium remains
unknown [16].
Previous studies have shown that chronic treatment of
animals [17,18] with lithium increases expression of the
anti-apoptotic gene BCL2 and decreases the expression
of the pro-apoptotic gene BAX. Treatment with lithium
has also been shown to block the reduction of the
BCL2/BAX ratio in animals treated with methampheta-
mine [19]. These findings have led to the suggestion
that changes in the expression of BCL2 and related
genes may be responsible for some or all of the thera-
peutic effects of lithium [17,20,21]. However, with
current technologies it is impossible to assess the time-
course of such changes in the brains of living subjects.
Thus, whether such changes occur in human patients
treated with lithium, and, if so, how they are related
to differences in treatment outcome among patients
remains unknown.
In a recently completed study conducted by our labora-
tory [22], we compared gene-expression profiles in whole
blood of depressed subjects with BD to that of healthy
controls. We identified a large number of genes whose
expression was altered in the blood of depressed BD sub-
jects. Strikingly, in that study, all of the top 10 functional
pathways identified were interconnected, and related dir-
ectly or indirectly to mitochondrial functions includingenergy metabolism and the regulation of apoptosis by
mitochondrial proteins. One advantage of studying
peripheral markers, including peripheral blood gene-
expression, is that they can be assessed repeatedly over
time, and thus compared directly to changes in clinical
status. In the present study, we sought to determine how
the peripheral blood gene expression profiles of patients
with BD changed over time when they were treated with
the mood stabilizer lithium, and whether differences




Subjects included in this study are identical to those
included in our previous publication [22]. All procedures
involving human subjects were approved by the Yale
Human Investigation Committee and are in accordance
with the Helsinki declaration of 1975. All subjects pro-
vided written informed consent at the time of enroll-
ment in the study. Inclusion criteria for subjects with
BD included age between 18 and 65 years, diagnosis of
bipolar disorder (bipolar type I or II), currently
depressed as defined by Diagnostic and Statistical Man-
ual of Mental Disorders, fourth edition text revision
(DSM-IV- TR) [23], and not being treated with lithium
at the time of study entry. Diagnosis was determined by
consensus of clinical interview by a Board Certified
Psychiatrist (RDB or ZB) and the Structured Clinical
Interview for DSM-IV Axis I Disorders [24] (performed
by KM, AM, or BL). Exclusion criteria included DSM-
IV-TR diagnoses other than bipolar I or II, current
or recent (past 30 days) abuse of illicit substances (veri-
fied by urine toxicology screening), pre-existing thyroid
pathology (e.g. hypothyroidism or hyperthyroidism) as
evidenced by an abnormal thyroid function test at
screening, or history or evidence of a medical condition
that would expose them to an undue risk of a significant
adverse event or interfere with assessments of safety or
efficacy during the course of the trial, including but not
limited to hepatic, renal, respiratory, cardiovascular,
endocrine, neurological, or hematological disease.
A total of 26 subjects with BD were recruited for this
study. To ensure that only BD subjects who had been
exposed to lithium for a period of time sufficient to
assess response were included in the gene-expression
analysis, an a priori decision was made to include only
those subjects who completed at least one month of
treatment. A total of 20 subjects were included; one sub-
ject was withdrawn due to previously undiagnosed
hypothyroidism, and five subjects dropped out of treat-
ment without completing one month of treatment.
Demographic and clinical information for the 20 sub-
jects included in the study is summarized in Table 1.






N (%) N (%)
Male 2 (20) 4 (40)
Female 8 (80) 6 (60)
Ethnicity
Caucasian 7 (70) 9 (90)
Non-caucasian 3 (30) 1 (10)
Bipolar I disorder 7 (70) 10 (100)
Mean± SD Mean± SD
Age 34.5 ± 10.6 42.0 ± 6.6
HAM-D (at entry) 26.2 ± 15.9 29.1 ± 14.8
HAM-A (at entry) 14.4 ± 8.6 14.7 ± 7.0
MADRS (at entry) 17.9 ± 11.6 20.7 ± 11.5
YMRS (at entry) 6.3 ± 5.8 5.9 ± 4.3
Lithium Level (average) 0.63 ± 0.14 0.65 ± 0.28
HAM-D=Hamilton Depression Rating Scale, HAM-A=Hamilton Anxiety Rating
Scale, MADRS =Montgomery-Asberg Depression Rating Scale, YMRS = Young
Mania Rating Scale.
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(5 male, 10 female) was recruited through advertising.
None of the control subjects met criteria for any DSM-
IV-TR axis I diagnosis as determined by the Structured
Clinical Interview for DSM-IV Axis I Disorders [24] or
current or recent abuse of illicit substances.
Treatments
All subjects received open label treatment with Lithium
carbonate in addition to their previous psychiatric medi-
cations. Lithium was started at an initial dose of 300 mg
p.o. BID. Doses were adjusted weekly based on lithium
trough levels until a target level of 0.6 to 1.2 mEq/L was
achieved or patients were unable to tolerate side effects.
Of the 20 subjects included in the microarray analysis,
there were 9 patients who were initially receiving no
medication and 11 who were receiving one or more atyp-
ical antipsychotic medications (olanzapine, quietapine,
risperidone, or ziprasidone). Two subjects were taking
valproic acid in addition to an atypical antipsychotic and
one subject each was taking carbamazepine, oxcarbaze-
pine or topiramate in addition to an atypical anti-
psychotic. Mood ratings for BD subjects were performed
using Hamilton Depression Rating Scale (HAM-D)
[25,26], the Montgomery-Asberg Depression Rating
Scale (MADRS) [27], Hamilton Anxiety Rating Scale
[28], and the Young Mania Rating Scale (YMRS) [29].
Sample Preparation and Microarray Analysis
Blood draws for RNA isolation were done prior to initi-
ation of treatment with lithium and every two weeksduring 8-weeks of open label treatment with lithium for
subjects with BD (five blood draws total). Blood draws
for RNA isolation were done at the same time as those
used to assess lithium trough levels, approximately
12 hours after the evening dose of lithium, and before
the morning dose was taken. Total RNA was isolated
from 10 cc whole blood using the PAXgene Blood RNA
Isolation kit (QIAGEN, Valencia, CA) per the manufac-
turer's instructions, and depleted of globin mRNA
message using GLOBINclear hybridization capture tech-
nology (Ambion, Austin, TX). Globin-reduced total
RNA underwent cDNA synthesis and overnight in vitro
transcription utilizing the Illumina TotalPrep RNA
Amplification Kit (Ambion). Biotinylated cRNA (1.5 μg)
was hybridized onto an Illumina Sentrix Beadchip
(Human-6v2) then scanned on a BeadArray Reader.
Microarray hybridization and scanning were carried out
at the NIH Neuroscience Microarray Center at Yale
(http:/info.med.yale.edu/neuromicroarray). Per the pol-
icies of the NIH microarray consortium, the complete
project annotation in MAGE-ML, image files, as well
as raw data files will be available for download. At
the time of publication, all data will be deposited into
the NCBI-GEO repository, while retaining links to the
microarray consortium relational data warehouse.
Data Analysis
BD subjects were divided into lithium-responders and
non-responders based on the a priori defined change
from their initial HAM-D scores. Lithium-responders
were defined as those having a >50% reduction in initial
HAM-D at the time of the last assessment. BD sub-
jects who did not meet these criteria were classified
as "non-responders". Subjects who dropped out during
weeks 4–8 were classified as lithium-responders or non-
responders using an intent-to-treat analysis based on the
last observation carried forward. Classification of BD
subjects as lithium-responders vs. non-responders did
not change if the MADRS was used instead of the
HAM-D to classify subjects.
Statistical analysis of microarray data was carried
out at the Keck Foundation Biotechnology Biostatistics
Resource (http://keck.med.yale.edu/biostats). Illumina
BeadStudio software was used to generate probe and gene
expression profiles of each sample. Quantile normalization
was carried out using the package incorporated in the
Illumina BeadStudio software package [30]. Further sta-
tistical analysis was carried out on genes with a detection
p-value <0.01 as determined using the Illumina BeadStudio
software (i.e. a 99% probability that expression was above
background) in 90% of the samples. A total of 17,240
genes on the array met these criteria. This is similar to
the detection sensitivity seen in other studies of whole
blood using the Illumina Sentrix Beadchip platform [31].
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lithium-responders and non-responders were assessed
using t-tests as well as ANOVA analysis co-varied for
age, sex, and co-administered medications. To identify
genes whose expression changed differentially in lithium
responders and non-responders after initiation of treat-
ment, we performed a mixed model ANOVA of the
complete microarray data set with group (responder or
non-responder) as a between subjects factor, and time as
a within subjects factor. Correction for multiple testing
was done using estimated group-wise false discovery
rates (FDR) [32,33].
Network analysis to identify the most significant path-
ways among genes identified by the ANOVA analysis
(above) was carried out using GeneGO MetacoreW soft-
ware (GeneGO Inc., Encinitas, CA).
qRT-PCR analysis
qRT-PCR was carried out using the TaqManW "Universal
PCR Master Mix" Protocol (Applied Biosystems) and
Real-Time PCR probes listed on the NCBI Probe Data-
base (http://www.ncbi.nlm.nih.gov/sites/entrez?db=probe).
Relative quantitation of gene-expression was done by
comparing the efficiency of amplification of each gene
of interest using the ΔΔCt method, as described in User
Bulletin#2 for the ABI Prism 7700 Sequence Detection
System (Applied Biosystems, available online at http://
keck.med.yale.edu/affymetrix/rtpcr/index.htm).
Results
Lithium responders did not differ significantly from non-
responders in their initial HAM-D, HAM-A, MADRS
or YMRS scores, age, sex, ethnicity, or use of concomi-
tant antipsychotic medication, however there was a
non-significant trend for greater use of antipsychotic med-
ications among the lithium non-responders. Average
serum levels of lithium over the eight weeks of treat-
ment did not differ significantly between responders
and non-responders (responders: 0.63 ± 0.14; non-
responders: 0.66 ± 0.28). Comparison of baseline
(pre-treatment) expression profiles between lithium
responders and non-responders using t-tests identified
606 genes, whose expression differed by ≥ 1.3 fold with
a nominal p-value <0.05. However, when other factors
such as age, sex, and use of co-administered medica-
tions were included as co-variates in an ANOVA
model, none of these differences were significant after
correction for multiple testing (FDR <0.05) (data not
shown). Thus, it is unclear whether any of these pre-
treatment differences are specifically associated with
the subsequent response to lithium.
Next, to identify genes whose expression changed
differentially in lithium responders and non-responders
after initiation of treatment, we performed a mixed modelANOVA of the complete microarray data set with group
(responder or non-responder) as a between subjects
factor, and time (in weeks, after starting treatment with
lithium) as a within subjects factor. There were 127 genes
that showed a significant group x time interaction (i.e.
difference in degree or direction of change between
lithium-responders and non-responders) after FDR cor-
rection for multiple testing, and a fold-difference≥ 1.3
between lithium responders and non-responders at least
one time-point after treatment initiation. Interestingly,
all of the significant differences between responders and
non-responders occurred during the period from 4–
6 weeks after initiation of treatment with lithium. This
time period corresponds well with the typical 6–8-week
delay in the acute antidepressant effect of lithium in the
treatment of bipolar depression [34]. At week 4 there
were 37 differentially expressed genes (22 up-regulated in
responders vs. non-responders and 15 down-regulated)
and at week 6 there were 90 differentially expressed genes
(51 up-regulated and 39 down-regulated). The complete
list of genes showing a significant group x time inter-
action is listed in Additional file 1 Table S1.
To better understand the functional implications of
these differences, we conducted pathway analysis using
GeneGO Metacore software for each of these clusters
separately, and for the group of 127 genes as a whole.
As seen in Table 2, 4 of the top 10 GeneGO Process Net-
works associated with the group as a whole are related
to the regulation of apoptosis, although most of these
pathways did not reach statistical significance. Moreover,
when considered separately, each of the clusters of differ-
entially expressed genes was related to one or more
apoptotic pathways, although again, many of these path-
ways did not reach statistical significance. Notably, at
4 weeks after treatment initiation, pro-apoptotic mito-
chondrial genes appears to be down-regulated, while anti-
apoptosis pathways regulated by external signals via PI3K/
AKT appeared to be up-regulated in lithium-responders
vs. non-responders. Based on these findings, as well as
previous work implicating the Bcl2 family of proteins in
the mechanism of action of lithium [17,18], we decided to
examine the pattern of expression of various Bcl2 gene
family members over time in lithium-responders and non-
responders more closely.
Table 3 shows the expression level of various pro- and
anti-apoptotic Bcl2 gene family member expression in
lithium-responders and non-responders (normalized to
healthy controls) as well as the ratio between responders
and non-responders over the course of eight weeks fol-
lowing initiation of treatment with lithium. Strikingly,
following initiation of treatment with lithium, all of the
anti-apoptotic genes examined (BCL2, BCL2L1-tx var. 1,
IRS2, and MCL1- tx. var. 1), showed an increase in
relative expression in lithium responders compared to
Table 2 Biological pathways identified by GeneGO metacore pathway analysis as differing over time between BD
subjects who responded or failed to respond to treatment with lithium
GeneGO Process Networks for genes showing significant group x time interaction
Overall p-Value
1 Apoptosis_Anti-Apoptosis mediated by external signals 0.013
2 Apoptosis_Apoptotic mitochondria 0.055
3 Cytoskeleton_Actin filaments 0.055
4 Apoptosis_Endoplasmic reticulum stress pathway 0.068
5 Cell cycle_Core 0.110
6 Protein folding_Folding in normal condition 0.117
7 Cell cycle_G1-S Interleukin regulation 0.123
8 Development_Hemopoiesis, Erythropoietin pathway 0.143
9 Immune response_BCR pathway 0.147
10 Apoptosis_Apoptosis stimulation by external signals 0.159
Week 4: down-regulated genes in Lithium responders vs. non-responders
1 Apoptosis_Apoptotic mitochondria 0.053
2 Apoptosis_Endoplasmic reticulum stress pathway 0.060
3 Signal transduction_Nitric oxide signaling 0.061
4 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 0.068
5 Protein folding_Folding in normal condition 0.081
6 Proteolysis_Proteolysis in cell cycle and apoptosis 0.085
7 Development_Hemopoiesis, Erythropoietin pathway 0.092
8 Apoptosis_Apoptosis stimulation by external signals 0.098
9 Proliferation_Negative regulation of cell proliferation 0.123
10 Cell adhesion_Amyloid proteins 0.127
Week 4: up-regulated genes in Lithium responders vs. non-responders
1 Cell adhesion_Glycoconjugates 0.010
2 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 0.017
3 Autophagy_Autophagy 0.053
4 Signal transduction_Androgen receptor signaling cross-talk 0.069
5 Signal transduction_ERBB-family signaling 0.072
6 Cytoskeleton_Macropinocytosis and its regulation 0.081
7 Inflammation_IL-13 signaling pathway 0.087
8 Signal transduction_Leptin signaling 0.098
9 Signal Transduction_Cholecystokinin signaling 0.100
10 Inflammation_IL-4 signaling 0.108
Week 6: down-regulated genes in Lithium responders vs. non-responders
1 Cell cycle_Core 0.027
2 Development_Hemopoiesis, Erythropoietin pathway 0.036
3 Response to hypoxia and oxidative stress 0.053
4 Transport_Synaptic vesicle exocytosis 0.059
5 Cell cycle_G0-G1 0.149
6 Neurophysiological process_Long-term potentiation 0.170
7 Blood coagulation 0.193
8 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 0.202
9 Inflammation_IL-6 signaling 0.238
10 Cell cycle_G1-S Interleukin regulation 0.245
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Table 2 Biological pathways identified by GeneGO metacore pathway analysis as differing over time between BD
subjects who responded or failed to respond to treatment with lithium (Continued)
Week 6: up-regulated genes in Lithium responders vs. non-responders
1 Development_Skeletal muscle development 0.024
2 Cell adhesion_Attractive and repulsive receptors 0.034
3 Cytoskeleton_Actin filaments 0.034
4 Development_Neurogenesis:Axonal guidance 0.056
5 Protein folding_ER and cytoplasm 0.074
6 Protein folding_Response to unfolded proteins 0.111
7 Apoptosis_Apoptotic mitochondria 0.123
8 Apoptosis_Endoplasmic reticulum stress pathway 0.138
9 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 0.156
10 Protein folding_Folding in normal condition 0.184
Pathway analysis was conducted for the entire group of 127 genes showing a significant group x time interaction, as well as for up-regulated and down-regulated
genes separately at each of the time-points where significant differences were seen (4 weeks and 6 weeks after treatment initiation).
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BCL2L1, this increase peaked at 2 weeks after treatment
initiation, while for the other genes the highest relative
expression occurred at 4 weeks. Among the pro-
apoptotic genes, BAD, BAK, BAX, and BMF showed a
decrease in the relative expression in lithium responders,
while BCL2L13, BCL2L1-tx. var. 2, BID, BNIP3, and
MCL1, tx. var. 2, showed no change or inconsistent
change over this time period. Thus, overall there
appeared to be an increase in the relative expression of
anti-apoptotic genes and a decrease in the expression of
pro-apoptotic genes in lithium responders during the
first month of treatment, while the opposite pattern was
seen in lithium non-responders. This pattern was even
more marked when the ratios of specific anti- and pro-
apoptotic genes were compared in lithium responders
and non-responders over time. Figure 1 shows the ratios
of BCL2/ BAD (panel A), BCL2/BAK1 (panel B), IRS2/
BAD (panel C) and IRS2/BAK1 (panel D) in lithium
responders and non-responders over the 8 weeks of the
study. In each case, the ratio of anti- to pro-apoptotic
genes increased in lithium responders over the first
month of treatment and then returned to baseline, while
the opposite pattern was observed in lithium non-
responders. When the ratios of alternatively spliced
versions of the same gene with either anti- or pro- apop-
totic functions (e.g. BCL2L1 tx. variants 1 and 2, or
MCL1 tx. variants 1 and 2) were compared, there was
no significant group x time interaction, indicating that
alternative splicing was not responsible for these effects.
We also performed qRT-PCR analysis of the 4 genes
shown in Figure 1: BCL2, IRS2, BAK1 and BAD, and com-
pared the ratio of anti-apoptotic to pro-apoptotic gene
expression in lithium responders and non-responders
4 weeks after treatment initiation. In general, the results of
the qRT-PCR analysis were similar to those obtained bymicroarray hybridization, with lithium-responders showing
greater relative expression of anti-apoptotic genes than
non-responders (BCL2/BAK1: 1.37 fold higher in respon-
ders vs. non-responders, BLC2/BAD: 1.69 fold higher
in responders vs. non-responders, IRS2/BAK1: 1.04 fold
higher in responders vs. non-responders, IRS2/BAD: 1.29
fold higher in responders vs. non-responders). However,
due to the greater variability in the qRT-PCR results, none
of these differences was statistically significant.
Discussion
In this study, we compared changes in gene-expression
in peripheral blood among a group of depressed subjects
with BD over a period of eight weeks following the
initiation of treatment with lithium. We identified 127
genes whose expression changed differentially in lithium
responders and non-responders. Pathway analysis of
the differentially expressed genes using GeneGO Meta-
core software showed that regulation of apoptosis was
the most significantly affected pathway among these
genes. Strikingly, among lithium responders, several anti-
apoptotic genes including BCL2 and insulin receptor sub-
strate 2 (IRS2) were up-regulated, while pro-apoptotic
genes, including BCL2-antagonist/killer 1 (BAK1) and
BCL2-associated agonist of cell death (BAD), were down-
regulated. In contrast, in lithium non-responders, BCL2
and IRS2 were down-regulated, while BAK1 and BAD
up-regulated at the one-month time-point.
BCL2 gene family members are key regulators of
apoptotic cell death and include both pro- and anti-
apoptotic genes [35,36]. Collectively, the expression
levels of the various BCL2 family members define
thresholds for apoptosis in a given cell. The two pro-
apoptotic proteins, BAX and BAK1 promote apoptosis
by binding to the mitochondrial voltage-dependent
anion channel (VDAC), and accelerating its opening,
Table 3 Expression of anti- and pro-apoptotic Bcl2-related genes in lithium responders and non-responders
(normalized to expression levels in untreated healthy controls subjects) at each of the time points tested (baseline,
2,4,6, and 8 weeks after treatment initiation)
Normalized Expression Levels Time (in weeks) since starting lithium
Anti-Apoptotic Genes Baseline 2 weeks 4 weeks 6 weeks 8 weeks
BCL2
Lithium Responders 0.96 0.89 1.08 0.86 0.83
Non-Responders 0.94 0.90 0.78 0.88 0.93
Ratio 1.0 1.0 *1.4 1.0 0.9
BCL2L1 (tx var. 1) (aka BCL-xL)
Lithium Responders 2.30 4.69 2.38 2.49 5.84
Non-Responders 3.04 3.49 2.08 3.13 1.85
Ratio 0.8 1.3 1.1 0.8 3.2
IRS2
Lithium Responders 0.78 1.12 1.51 0.84 1.35
Non-Responders 1.22 0.99 0.68 1.00 1.13
Ratio 0.6 1.1 ***2.2 0.8 1.2
MCL1 (tx. Var. 1)
Lithium Responders 0.56 0.81 0.91 0.74 0.98
Non-Responders 1.18 1.00 0.79 1.02 1.05
Ratio **0.5 0.8 1.1 0.7 0.9
Pro-Apoptotic Genes
BAD
Lithium Responders 1.54 1.49 1.29 1.44 1.32
Non-Responders 1.39 1.39 1.48 1.33 1.41
Ratio 1.1 1.1 0.9 1.1 0.9
BAK1
Lithium Responders 1.47 0.92 0.80 0.89 0.76
Non-Responders 1.29 1.08 1.23 1.24 1.29
Ratio 1.1 0.9 ***0.6 **0.7 0.6
BAX
Lithium Responders 1.69 1.73 1.55 1.58 1.18
Non-Responders 1.14 1.39 1.25 1.42 1.53
Ratio **1.5 1.2 1.2 1.1 0.8
BCL2L13 (aka BCL-Rambo)
Lithium Responders 0.86 0.98 0.96 0.82 0.96
Non-Responders 0.96 1.03 0.86 0.97 0.85
Ratio 0.9 0.9 1.1 0.8 1.1
BCL2L1 (tx var. 2)(aka BCL-xL)
Lithium Responders 1.58 2.34 1.54 1.42 1.54
Non-Responders 1.58 1.98 1.59 1.96 1.36
Ratio 1.0 1.2 1.0 0.7 1.1
BID
Lithium Responders 1.03 1.06 1.09 0.98 1.01
Non-Responders 1.04 0.99 1.02 1.12 0.97
Ratio 1.0 1.1 1.1 0.9 1.0
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Table 3 Expression of anti- and pro-apoptotic Bcl2-related genes in lithium responders and non-responders
(normalized to expression levels in untreated healthy controls subjects) at each of the time points tested (baseline,
2,4,6, and 8 weeks after treatment initiation) (Continued)
BMF
Lithium Responders 1.09 1.05 1.06 1.06 0.96
Non-Responders 0.91 0.97 1.10 0.82 1.06
Ratio 1.2 1.1 1.0 *1.3 0.9
BNIP3
Lithium Responders 1.02 0.74 0.89 0.78 0.78
Non-Responders 0.81 0.84 0.77 0.82 0.91
Ratio **1.3 0.9 1.2 0.9 0.9
MCL1 (tx. var. 2)
Lithium Responders 1.08 1.21 1.14 1.10 1.34
Non-Responders 1.11 1.24 1.10 1.19 1.02
Ratio 1.0 1.0 1.0 0.9 *1.3
Following initiation of treatment with lithium, all of the anti-apoptotic genes examined (BCL2, BCL2L1-tx var. 1, IRS2, and MCL1- tx. var. 1), showed an increase in
the relative expression in lithium responders compared to non-responders during the first month of treatment. Among the pro-apoptotic genes, BAD, BAK, BAX,
and BMF showed a decrease in the relative expression in lithium responders, while BCL2L13, BCL2L1-tx. var. 2, BID, BNIP3, and MCL1, tx. var. 2, showed no change
or inconsistent change over this time period.
Significant differences are marked with asterisks (* p <0.10, ** p <0.05, and *** P < .01).
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cytochrome c, and subsequent activation of the intrinsic
caspase pathway. Anti-apoptotic members of the BCL2
family, including BCL2 itself, the related protein BCL-xL
(encoded by the BLCL1 gene) and MCL-1, prevent
apoptosis by binding to BAX and BAK1, preventing their
interaction with VDAC. Other pro-apoptotic BCL2 fam-
ily members, termed the ‘BH3-only’ proteins, including
BAD, BID, and BMF, are thought to indirectly promote
apoptosis by binding to anti-apoptotic family members
and preventing their interaction with BAX and BAK1
[35,36]. IRS2 is a cytoplasmic signaling molecule that
mediates effects of insulin, insulin-like growth factor 1,
and other cytokines by acting as a molecular adaptor be-
tween diverse receptor tyrosine kinases and downstream
effectors. In addition, IRS2 has been shown to bind to
the Bcl2 protein and block phosphorylation of Bcl2
induced by insulin and suppress apoptotic cell death
[37]. Thus, our finding that BCL2 and IRS2 are both
increased in lithium responders at the one month time
point, while BAK1 and BAD were down-regulated, sug-
gests that in lithium responders there was a shift in the
balance of expression among pro- and anti- apoptotic
members of the BCL2 family favoring the anti-apoptotic
genes. Conversely, in lithium non-responders there was
a decrease in BCL2 and IRS2 and an increase BAK1 and
BAD, suggesting that there was a shift in the opposite
direction, favoring the pro-apoptotic members of the
BCL2 family. Intriguingly, changes in the ratio of anti-
to pro-apoptotic gene expression among both lithium
responders and non-responders appeared to return to
baseline by the 8-week time-point, although differencesin clinical status were more marked at this point than at
4 weeks. This suggests that transient changes in gene-
expression can have enduring effects on the state of the
organism, even when those differences can no longer be
directly observed. Additional studies will be required to
determine if there are changes in the level or function of
the proteins encoded by these genes that are longer last-
ing and perhaps more directly related to the clinical sta-
tus of the patients.
While changes in the expression of BCL2 family genes
in peripheral blood are unlikely to be directly related to
the changes in mood symptoms, systemic differences in
the way subjects with different genetic and epigenetic
backgrounds respond at the biochemical level to treat-
ment with lithium may underlie some of the heterogen-
eity in clinical response to lithium.
Studies of post-mortem tissue from human subjects
has shown that activity of mitochondrial complex I is
decreased, and oxidative damage is increased in the pre-
frontal cortex of patients with BD [38]. Lithium has been
shown to increase the activity of mitochondrial ETC.
complexes in extracts from human post-mortem brain
tissue at therapeutically relevant concentrations [39],
while rats subjected to an experimental model of depres-
sion showed impaired mitochondrial function [40]. Con-
versely, transgenic mice expressing the anti-apoptotic
protein Bax Inhibitor 1, showed protection in the learned
helplessness model of depression [41]. These results have
been interpreted in the context of a neurotrophic hy-
pothesis of mood disorders [42,43], indicating that
increased expression of BCL2 and related genes is neces-
sary for the therapeutic effects of lithium and other
Figure 1 Ratios of BCL2/ BAD (panel A), BCL2/BAK1 (panel B), IRS2/BAD (panel C) and IRS2/BAK1 (panel D) in lithium responders and
non-responders over the 8 weeks of the study. In each case, the ratio of anti- to pro-apoptotic genes increased in lithium responders over
the first month of treatment and then returned to baseline, while the opposite pattern was observed in lithium non-responders.
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tial group of patients, this effect does not occur, and in
fact the opposite effect was seen in patients who did not
respond to lithium. Better understanding of the mechan-
isms underlying this difference may lead to improved
methods for personalizing treatment for bipolar disorder
in the future.
Limitations of this study include a relatively small
sample-size, admixture of subjects with BD I and BD II,
and the fact that BCL2 family members were assayed at
the level of gene-expression rather than protein or func-
tional assays. A further caveat is that while the average
Li level in both groups was similar, and was within our
target range of 0.6 to 1.2 mEq/L, there were several sub-
jects in both groups whose levels were outside of that
range, which may have affected both their response to
treatment and the patterns of gene-induction observed
in these subjects. In addition, these studies address only
the acute anti-depressant properties of lithium, and do
not address changes in gene-expression that may be
related to lithium’s anti-manic, prophylactic or anti-
suicide properties, each of which may be associated with
a unique molecular profile. Due to the small sample size
and limited information that was collected regarding
prior episodes, we are unable to address the relationship,if any, between these molecular changes and the pro-
posed specificity of lithium for “classic bipolar disorder”
as opposed to the broader spectrum of bipolar illnesses
[8]. Future studies will be needed to confirm these find-
ings in a larger cohort of patients and to determine the
relevancy of these changes to other aspects of lithium’s
clinical effects in patients with BD.
Conclusions
In this study, we compared changes in gene-expression
in peripheral blood among a group of depressed subjects
with BD over a period of eight weeks following the initi-
ation of treatment with lithium. We found that the
ratio of anti- to pro-apoptotic gene expression increased
in lithium responders over the first month of treatment
and then returned to baseline, while the opposite pattern
was observed in lithium non-responders. These results
suggest that individual differences in the response
to treatment with lithium occur at the level of gene-
induction, and are clinically relevant. If validated in lar-
ger studies, such changes could be useful clinically as
surrogate outcome markers allowing treatment decisions
(including whether to continue or discontinue treatment
with lithium) to be made earlier, and thus facilitate
recovery in patients with BD.
Lowthert et al. Biology of Mood & Anxiety Disorders 2012, 2:15 Page 10 of 11
http://www.biolmoodanxietydisord.com/content/2/1/15Additional file
Additional file 1: Table S1. Fold difference and p-value for each of 127
genes, grouped by cluster, that showed a significant group x time
interaction (i.e. difference in degree or direction of change between
lithium-responders and non-responders) after FDR correction for multiple
testing, and a fold-difference≥ 1.3 between lithium responders and non-
responders at least one time-point after treatment initiation.
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